SEC Form 4 · accession 0001179022-18-000044

GALECTIN THERAPEUTICS INC · GALT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

May 31, 2018

Accepted (ET)

Jun 4, 2018 · 4:51 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001133416

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	May 31, 2018	M	50,000	$2.32	A	103,914	D
Common Stock	May 31, 2018	S	50,000	$5.00	D	53,914	D
Common Stock	Jun 1, 2018	M	9,500	$2.32	A	63,414	D
Common Stock	Jun 1, 2018	M	59,700	$0.87	A	123,114	D
Common Stock^F4	Jun 1, 2018	S	69,200	$5.10	D	53,914	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F2	$2.32	May 31, 2018	M	50,000	D	—	Aug 27, 2022	Common Stock	50,000	100,000	D
Stock option (right to buy)^F2	$2.32	Jun 1, 2018	M	9,500	D	—	Aug 27, 2022	Common Stock	9,500	90,500	D
Stock option (right to buy)^F3	$0.87	Jun 1, 2018	M	59,700	D	—	Dec 3, 2026	Common Stock	59,700	90,300	D

F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018.
F2The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014.
F3The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.
F4The shares were sold in multiple transactions at prices ranging from $5.00 to $5.18. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.